Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of AC-084 in healthy subjects
NCT02905253Phase 1Terminated
- Sponsor
- Idorsia
- Start
- Sep 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACT-774312 in nasal polyps (5 arms), sponsored by Idorsia. Primary endpoints: Number of participants with adverse events (AEs) at Day 8 and Incidence of safety events of interest at Day 8. Started Sep 2016; status: terminated.
02
Drugs
ACT-774312
03
Conditions
nasal polyps
Beyond the preview
Go deeper on NCT02905253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905253.